These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

939 related articles for article (PubMed ID: 1102083)

  • 41. Experimental approach for the search of effective drug combination in cancer chemotherapy.
    Bello JL; Kariev NI; Mainardi JV; Betancourt M; Lage A; Barroso MC; Alfonso L
    Neoplasma; 1982; 29(1):65-71. PubMed ID: 7070556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adriamycin/cyclophosphamide combination chemotherapy: the importance of drug scheduling.
    Mulder JH; van Putten LM
    Eur J Cancer (1965); 1979 Dec; 15(12):1503-9. PubMed ID: 294960
    [No Abstract]   [Full Text] [Related]  

  • 43. Antitumor activity of 13-methyl-berberrubine derivatives.
    Ikekawa T; Ikeda Y
    J Pharmacobiodyn; 1982 Jul; 5(7):469-74. PubMed ID: 7131231
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
    Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
    Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The carcinostatic activity of alpha-(N) heterocyclic carboxaldehyde thiosemicarbazones. I. Isoquinoline-1-carboxaldehyde thiosemicarbazone.
    French FA; Blanz EJ
    Cancer Res; 1965 Oct; 25(9):1454-8. PubMed ID: 5862990
    [No Abstract]   [Full Text] [Related]  

  • 46. Optimal treatment schedule and antitumor spectrum of 4-carbamoylimidazolium 5-olate (SM-108) in murine tumors.
    Yoshida N; Nakamura M; Fukui M; Morisada S; Ogino S; Inaba M; Tsukagoshi S; Sakurai Y
    Cancer Res; 1983 Dec; 43(12 Pt 1):5851-6. PubMed ID: 6640536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Carcinostatic sulfonic acid esters of butyne- and butane-1,4-diols.
    Earl RA; Harmon RE
    J Med Chem; 1966 Sep; 9(5):776-8. PubMed ID: 5969056
    [No Abstract]   [Full Text] [Related]  

  • 48. In vivo anti-cancer activity of RC-18: a plant isolate from Rubia cordifolia, Linn. against a spectrum of experimental tumour models.
    Adwankar MK; Chitnis MP
    Chemotherapy; 1982; 28(4):291-3. PubMed ID: 7116981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antitumor activity of amidoximes (hydroxyurea analogs) in murine tumor systems.
    Flora KP; van't Riet B; Wampler GL
    Cancer Res; 1978 May; 38(5):1291-5. PubMed ID: 639062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Body burden of cancer in relationship to therapeutic outcome: consideration of preclinical evidence.
    Griswold DP
    Cancer Treat Rep; 1986 Jan; 70(1):81-6. PubMed ID: 3943116
    [No Abstract]   [Full Text] [Related]  

  • 51. [Acceleration of growth of transplantable tumors and change in the sensitivity to chemotherapy on administration of creatinine].
    Pukhal'skaia ECh; Platonova GN
    Biull Eksp Biol Med; 1971 Oct; 72(10):82-5. PubMed ID: 5126158
    [No Abstract]   [Full Text] [Related]  

  • 52. DDMP (2,4-diamino-5-(3',4'-dichlorophenyl)-methylpyrimidine).
    Hill BT; Price LA
    Cancer Treat Rev; 1980 Jun; 7(2):95-112. PubMed ID: 6996812
    [No Abstract]   [Full Text] [Related]  

  • 53. Potentially useful combinations of chemotherapy detected in mouse tumor systems.
    Kline I
    Cancer Chemother Rep 2; 1974 Mar; 4(1):33-43. PubMed ID: 4133187
    [No Abstract]   [Full Text] [Related]  

  • 54. Biologic activity of MCNU: a new antitumor agent.
    Sekido S; Ninomiya K; Iwasaki M
    Cancer Treat Rep; 1979 Jun; 63(6):961-70. PubMed ID: 466655
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rationale of combination chemotherapy based on preclinical experiments.
    Goldin A
    Cancer Chemother Rep 3; 1973 Mar; 4(2):189-98. PubMed ID: 4580857
    [No Abstract]   [Full Text] [Related]  

  • 56. Advantage of yeast polysaccharide-combined chemotherapy in mouse tumors.
    Kumano N; Nakai Y; Kurita K; Ishikawa T; Konno K
    Sci Rep Res Inst Tohoku Univ Med; 1978 Dec; 25(3-4):50-7. PubMed ID: 752924
    [No Abstract]   [Full Text] [Related]  

  • 57. Antitumor activity of 1,2-bis diazoacetyl ethane.
    Emanuel NM; Konovalova NP; Djachkovskaya RF
    Cancer Treat Rep; 1976 Nov; 60(11):1601-4. PubMed ID: 191190
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
    Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antitumor activity of DL-1-beta-chloroethyl-2-chloromethylpiperidine hydrobromide (CAP-1) on some rodent tumors.
    Koshiura R; Kato H; Mori T
    Jpn J Pharmacol; 1973 Aug; 23(4):535-41. PubMed ID: 4356998
    [No Abstract]   [Full Text] [Related]  

  • 60. 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone, a second-generation antineoplastic agent of the alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazone series.
    Agrawal KC; Schenkman JB; Denk H; Mooney PD; Moore EC; Wodinsky I; Sartorelli AC
    Cancer Res; 1977 Jun; 37(6):1692-6. PubMed ID: 870183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.